Cambrex Karlskoga Competitors and Similar CompaniesClear all

Cambrex Karlskoga's competitors and similar companies include Recipharm, Octapharma, Bausch Health Americas and Hypera Pharma.

	Cambrex Karlskoga Cambrex Karlskoga is a company that provides contract development and manufacturing organization (CDMO) services.	Recipharm Recipharm is a pharmaceutical contract development and manufacturing company.	Octapharma Octapharma is one of the largest human protein manufacturers, developing and producing human proteins from human plasma and human cell lines.	Bausch Health Americas Bausch Health Americas (BHA) is a pharmaceutical preparation manufacturing company.	Hypera Pharma Hypera Pharma is a pharmaceutical company that provides medicines and food supplements.
Founding Date	Founding Date 1916	Founding Date 1995	Founding Date 1983	Founding Date 1994	Founding Date 2001
Type	Type Subsidiary	Type Private	Type Private	Type Subsidiary	Type Public
Tags	Tags Manufacturing & Industrial drug development pharma	Tags Manufacturing & Industrial drug development pharma	Tags Manufacturing & Industrial drug development pharma	Tags Manufacturing & Industrial drug development pharma	Tags Manufacturing & Industrial drug development pharma
Locations	Locations Björkborn, SE HQ	Locations Stockholm, SE HQ Kaysersberg, FR Cuxhaven, DE Monheim Am Rhein, DE Wasserburg Am Inn, DE Zwickau, DE Bengaluru, IN see more	Locations Lachen, CH HQ Pyrmont, AU Wien, AT Baku, AZ Minsk, BY Anderlecht, BE see more	Locations Bridgewater, US HQ Laval, CA Steinbach, CA Envigado, CO La Estrella, CO Medellín, CO Ciudad De México, MX see more	Locations São Paulo, BR HQ
Employees	Employees 203	Employees 7,40915% decrease	Employees 12,000	Employees 4,044	Employees 10,481
Financial
Revenue (est.)	Revenue (est.) N/A	Revenue (est.) kr705.5m (FY, 2023)	Revenue (est.) €2.5b (FY, 2021)	Revenue (est.) N/A	Revenue (est.) R$7.7b (FY, 2025)
Cost of goods	Cost of goods N/A	Cost of goods N/A	Cost of goods €1.7b (FY, 2021)	Cost of goods N/A	Cost of goods R$2.8b (FY, 2025)
Gross profit	Gross profit N/A	Gross profit N/A	Gross profit €808.2m (FY, 2021)	Gross profit N/A	Gross profit R$4.9b (FY, 2025)
Net income	Net income N/A	Net income (kr8.8b) (FY, 2023)	Net income €438.3m (FY, 2021)	Net income N/A	Net income R$1.2b (FY, 2025)